Open Access

Late-Breaking Trials - Pharmacological treatment II

Event: Heart Failure 2022
Topic: Chronic Heart Failure
Session type: Late-Breaking Science
Date: 23 May 2022
Time: 15:50 - 16:50

Congress Session

This content is currently on OPEN ACCESS

Sign in to view the resources

5 presentations in this session

The safety and efficacy of istaroxime for PreCardiogenic Shock

Speaker: Professor M. Metra (Brescia, IT)

Short-term effects of dapagliflozin on peak VO2 in heart failure and reduced ejection fraction (DAPA-VO2): a randomized clinical trial

Speaker: Doctor J. Nunez Villota (Valencia, ES)

DIAMOND Trial: Patiromer for the Management of Hyperkalemia in Subjects Receiving RAASi Medications for Heart Failure with Reduced Ejection Fraction

Speaker: Professor B. Pitt (Ann Arbor, US)

EMPULSE - EMPagliflozin in patients hospitalized with acUte heart faiLure who have been StabilizEd

Speaker: Professor P. Ponikowski (Wroclaw, PL)

FIDELITY: Effect of finerenone by LVH subgroup

Speaker: Professor G. Filippatos (Athens, GR)

5 speakers from this session

Professor Marco Metra

University of Brescia, Brescia (Italy)
81 presentations

Doctor Julio Nunez Villota

University of Valencia, Valencia (Spain)
6 presentations
0 follower

Professor Bertram Pitt

University of Michigan, Ann Arbor (United States of America)
19 presentations
0 follower

Professor Piotr Ponikowski

Wroclaw Medical University, Wroclaw (Poland)
67 presentations

Professor Gerasimos Filippatos

National & Kapodistrian University of Athens Medical School, Athens (Greece)
55 presentations
1 follower

Related content

Open Access

Update on endocarditis in 2021

3 December 2021

Open Access

Current controversies in antithrombotic therapy

3 December 2021

Open Access

Opening session

2 December 2021

This platform is supported by

logo Novo Nordisk